Entering text into the input field will update the search result below

Coagulation Analyzer Market Market Development And Business Intelligence

Feb. 18, 2021 7:18 AM ET
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Summary

  • Major factors influencing the growth of the market.
  • Leading players & Top Segments.
  • Geographic Overview.

Market growth influenced due to following factors-

  • Increasing prevalence of cardiovascular diseases and blood disorders.
  • Technological advancements in coagulation analyzers.
  • Rising geriatric population.

Global market size-

According to market research report the global Coagulation Analyzer Market is projected to reach $5.0 billion by 2025, at a CAGR of 5.7% between 2020 and 2025. 

Leading Players-

Siemens Healthineers (Germany), Thermo Fisher Scientific (US), Roche Diagnostics (Switzerland), Alere, Inc. (US), Sysmex Corporation (Japan), Nihon Kohden Corporation (Japan), Diagnostica Stago (France), Helena Laboratories (US), and Horiba Medical (Japan) are some of the key players operating in this Coagulation Analyzer Market.

Top Market Segments-

Based on product, the Hemostasis Analyzer Market is segmented into clinical laboratory analyzers and point-of-care testing analyzers. In 2019, the clinical laboratory analyzers segment accounted for a larger share of the market.

On the basis of end user, the Hemostasis Analyzer Market is segmented into clinical laboratories, hospitals, and other end users. In 2019, the clinical laboratories segment accounted for the largest share of the market.

For Details, Download PDF Brochure Here

Geographic Overview -

North America (comprising the US and Canada) accounted for the largest share of the global Coagulation Analyzer Market in 2019, followed by Europe. Factors such as the increasing prevalence of lifestyle diseases and the rising incidence of blood disorders are stimulating the growth of the market in North America.

 

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.